Shared on08 Aug 25Fair value Increased 15%
The upward revision in Silence Therapeutics’ price target reflects significantly improved consensus revenue growth forecasts and a lower future P/E multiple, resulting in an increased fair value estimate from $32.37 to $37.26. What's in the News Silence Therapeutics approved the application of Article 159 of its articles of association, effective from the recent AGM to the next annual general meeting.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 24%
AnalystConsensusTarget has increased revenue growth from 16.4% to 61.6%, increased profit margin from 10.5% to 76.3% and decreased future PE multiple from 318.7x to 12.9x.